Neurognostics Report issue

For profit Phase 4
Founded: Milwaukee WI United States (2003)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2004
NCT00315367
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

Neurognostics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Sclerosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3